Literature DB >> 3735544

Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases.

E D Crawford, D McKenzie, W Mansson, M Totonchy, H B Grossman, M Davis, D L Lamm, M Duchek.   

Abstract

We report 6 cases of adverse systemic reactions to the intravesical instillation of doxorubicin hydrochloride for the treatment of recurrent superficial transitional cell carcinoma of the bladder. Although local reactions to this drug are common they rarely are life-threatening. Significant systemic toxicity has not been reported.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3735544     DOI： 10.1016/s0022-5347(17)45010-5

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


  3 in total

Review 1.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Prospective randomized study of prophylaxis of superficial bladder cancer with epirubicin: the role of a central pathology laboratory. Nara Uro-oncology Research Group. (NUORG).

Authors:  Y Hirao; S Ozono; H Momose; E Okajima; T Hiramatsu; K Yoshida; S Fukushima; Y Ohashi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Current recommendations for the management of bladder cancer. Drug therapy.

Authors:  J A Witjes
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.